Law Firm Brower Piven Announces Investigation of Onyx Pharmaceuticals, Inc. Proposed Buyout
August 26 2013 - 11:07AM
Business Wire
The securities litigation firm of Brower Piven, A Professional
Corporation, has commenced an investigation into possible breaches
of fiduciary duty to current shareholders of Onyx Pharmaceuticals,
Inc. (“Onyx Pharmaceuticals” or the “Company”) (NasdaqGS: ONXX) and
other violations of state law by the board of directors of Onyx
Pharmaceuticals relating to the proposed buyout of the Company by
Amgen Inc. The firm’s investigation seeks to determine, among other
things, whether the board of directors of Onyx Pharmaceuticals
breached their fiduciary duties by failing to maximize shareholder
value.
According to the press release announcing the proposed buyout,
Onyx Pharmaceuticals shareholders will receive $125.00 per share in
cash for each share of Onyx Pharmaceuticals common stock they own.
According to Yahoo! Finance, the high analyst price target is
$160.00 per Onyx Pharmaceuticals share.
If you currently own common stock of Onyx Pharmaceuticals and
would like to learn more about the investigation being conducted by
Brower Piven, you may email or call Brower Piven, who will, without
obligation or cost to you, attempt to answer your questions. You
may contact Brower Piven by email at hoffman@browerpiven.com, by
calling (410) 415-6616, or at Brower Piven, A Professional
Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153.
Attorneys at Brower Piven have combined experience litigating
securities and other class action cases of over 60 years.
Brower Piven, A Professional CorporationStevenson,
MarylandCharles J. Piven, 410-415-6616hoffman@browerpiven.com
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024